BC
CADL icon

Birchview Capital’s Candel Therapeutics CADL Stock Holding History

Birchview Capital’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$492K Sell
47,756
-12,244
-20% -$92.5K 0.23% 53
2026
Q1 		$294K Hold
60,000
– – 0.17% 62
2025
Q4 		$339K Hold
60,000
– – 0.2% 59
2025
Q3 		$306K Hold
60,000
– – 0.23% 59
2025
Q2 		$304K Hold
60,000
– – 0.3% 51
2025
Q1 		$339K Hold
60,000
– – 0.29% 40
2024
Q4 		$521K Buy
+60,000
New +$355K 0.42% 31

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Birchview Capital's CADL Position: Q2 2026 in Review

Birchview Capital reduced its Candel Therapeutics (CADL) stake by 20% in Q2 2026, selling an estimated $92.5K and leaving 47,756 shares worth $492K. The position accounts for 0.23% of the portfolio, ranked #53.

Birchview Capital first reported a position in CADL in Q4 2024 and has held it in 7 quarters since. The position peaked at $521K in Q4 2024. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Birchview Capital held 47,756 shares of Candel Therapeutics worth $492K as of Q2 2026.
  • Birchview Capital sold 12,244 Candel Therapeutics shares in Q2 2026, an estimated $92.5K.
  • Candel Therapeutics made up 0.23% of Birchview Capital's portfolio in Q2 2026, its #53 holding.
  • Birchview Capital first reported a position in Candel Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Birchview Capital's Candel Therapeutics position peaked at $521K in Q4 2024.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.